Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of α-synuclein

Biochemistry

Volumn 46, Issue 2, 2007, Pages 472-482

  Follmer, Cristian ^a   Romão, Luciana ^a   Einsiedler, Carla M ^a   Porto, Thaís C R ^a   Lara, Flávio Alves ^a   Moncores, Marlos ^a   Weissmüller, Gilberto ^a   Lashuel, Hilal A ^b   Lansbury, Peter ^c,d   Neto, Vivaldo Moura ^a   Silva, Jerson L ^a   Foguel, Debora ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b EPFL   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; ATOMIC FORCE MICROSCOPY; HYDROSTATIC PRESSURE; OLIGOMERS; STABILITY; TOXICITY;

CYTOPLASMIC INCLUSIONS; DOPAMINERGIC NEURONS; HIGH HYDROSTATIC PRESSURE (HHP); PARKINSON'S DISEASE (PD);

DISEASES;

ALPHA SYNUCLEIN; DOPAMINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BRAIN CELL; CELL INCLUSION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HYDRATION; HYDROSTATIC PRESSURE; MESENCEPHALON; MOUSE; MUTATION; NEURITE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STABILITY;

ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; DOPAMINE; DRUG STABILITY; HUMANS; HYDROSTATIC PRESSURE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON; MULTIPROTEIN COMPLEXES; NEURONS; PARKINSON DISEASE; RECOMBINANT PROTEINS; VARIATION (GENETICS); WATER;

EID: 33846210629     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi061871+     Document Type: Article

References (48)

1. Tanner, C. M. (1992) Occupational and environmental causes of parkinsonism, Occup. Med. 7, 503-513.
2. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowsky, J. Q., Jakes, R., and Goldberg, M. (1997) α-Synuclein in Lewy bodies, Nature 388, 839-840.
3. Forno, L. S. (1996) Neuropathology of Parkinson's disease, J. Neuropathol. Exp. Neurol. 55, 259-272.
4. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl Acad. Sci. U.S.A. 95, 6469-6473.
5. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowsky, J. Q., and Iwatsubo, T. (1998) Aggregation of a-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am. J. Pathol. 152, 879-884.
6. Goedert, M., Spillantini, M. G., Serpell, L. C., Berriman, J., Smith, M. J., Jakes, R., and Crowther, R. A. (2001) From genetics to pathology: tau and α-synuclein assemblies in neurodegenerative diseases, Philos. Trans. K. Soc. London, Ser. B 356, 213-227.
7. Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., Lu, B., and Nussbaum, R. L. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein, J. Neurosci. 22, 8797-8807.
8. Cookson, M. R. (2005) The biochemistry of Parkinson's disease, Annu. Rev. Biochem. 74, 29-52.
9. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease, Science 276, 2045-2047.
10. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease, Nat. Genet. 18, 106-108.
11. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy, Proc. Nat. Acad. Sci. U.S.A. 97, 571-576.
12. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) α-Synuclein locus triplication causes Parkinson's disease, Science 302, 841-843.
13. Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S., and Giusti, P. (2004) α-Synuclein and Parkinson's disease, FASEB J. 18, 617-626.
14. Goldberg, M. S., and Lansbury, P. T. (2000) Is there a cause-and-effect relationship between α-synuclein fibrillation and Parkinson's disease? Nat. Cell Biol. 2, 115-119.
15. Rochet, J. C., Outeiro, T. F., Conway, K. A., Ding, T. T., Volles, M. J., Lashuel, H. A., Bieganski, R. M., Lindquist, S. L., and Lansbury, P. T. (2004) Interactions among α-synuclein, dopamine, and biomembranes: Some clues for understanding neurodegeneration in Parkinson's disease, J. Mol. Neurosci. 23, 23-34.
16. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders, Science 87, 1265-1269.
17. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein, Biochemistry 40, 11604-11613.
18. Li, J., Uversky, V. N., and Fink, A. L. (2002) Conformational behavior of human α-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T, Neurotoxicology 23, 553-567.
19. Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., and Giasson, B. I. (2005) The E46K mutation in α-synuclein increases amyloid fibril formation, J. Biol. Chem. 280, 7800-7807.
20. Volles, M. J., and Lansbury, P. T. (2002) Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism, Biochemistry 41, 4595-4602.
21. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T. (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct, Science 294, 1346-1349.
22. Li, J., Zhu, M., Manning-Bog, A. B., Di Monte, D. A., and Fink, A. L. (2004) Dopamine and L-dopa disaggregate amyloid fibrils: Implications for Parkinson's and Alzheimer's disease, FASEB J. 18, 962-964.
23. Foguel, D., Suarez, M. C., Ferrão-Gonzales, A. D., Porto, T. C. R., Palmieri, L., Einsiedler, C. M., Andrade, L. R., Lashuel, H. A., Lansbury, P. T., Kelly, J. W., and Silva, J. L. (2003) Dissociation of amyloid fibrils of α-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities, Proc. Natl. Acad. Sci. U.S.A. 100, 9831-9836.
24. Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen, A. O., Riekel, C., Grothe, R., and Eisenberg, D. (2005) Structure of the cross-β spine of amyloid-like fibrils, Nature 435, 747-749.
25. Tycko, R. (2006) Molecular structure of amyloid fibrils: Insights from solid-state NMR, Q. Rev. Biophys. 1-55.
26. Cappai, R., Leek, S. L., Tew, D. J., Williamson, N. A., Smith, D. P., Galatis, D., Sharples, R. A., Curtain, C. C., Ali, F. E., Cherny, R. A., Culvenor, J. G., Bottomley, S. P., Masters, C. L., Barnham, J. K., and Hill, A. F. (2005) Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway, FASEB J. 19, 1377-1379.
27. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease, Nat. Med. 4, 1318-1320.
28. Silva, J. L., Silveira, C. F., Correa, A., and Pontes, L. (1992) Dissociation of a native dimer to a molten globule monomer. Effects of pressure and dilution on the association equilibrium of arc repressor, J. Mol Biol. 223, 545-555.
29. Prochiantz, A., Daguet, M. C., Herbet, A., and Glowinski, J. (1981) Specific stimulation of in vitro maturation of mesencephalic dopaminergic neurons by striatal membranes, Nature 293, 570-572.
30. Garcia-Abreu, J., Neto, V. M., Carvalho, S. L., and Cavalcante, L. A. (1995) Regionally specific properties of midbrain glia: I. interactions with midbrain neurons, J. Neurosci. Res. 40, 471-477.
31. Sousa, V. de O., Romao, L., Neto, V. M., and Gomes, F. C. (2004) Glial fibrillary acidic protein gene promoter is differently modulated by transforming growth factor-β 1 in astrocytes from distinct brain regions, Eur. J. Neurosci. 19, 1721-1730.
32. Volles, M. J., and Lansbury, P. T. (2003) Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease, Biochemistry 42, 7871-7878.
33. Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., and Lee, V. M. (2005) Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations, J. Biol. Chem. 280, 21212-21219.
34. Jimenez, J. L., Tennent, G., Pepys, M., and Saibil, H. R. (2001) Structural diversity of ex vivo amyloid fibrils studied by cryoelectron microscopy, J. Mol. Biol. 311, 241-247.
35. Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W. M., Mattson, M. P., and Tycko, R. (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils, Science 307, 262-265.
36. Dirix, C., Meersman, F., MacPhee, C. E., Dobson, C. M., and Heremans, K. (2005) High hydrostatic pressure dissociates early aggregates of TTR105-115, but not the mature amyloid fibrils, J. Mol. Biol. 347, 903-909.
37. Chatani, E., Naiki, H., and Goto, Y. (2006) Seeding-dependent propagation and maturation of β2-microglobulin amyloid fibrils under high pressure, J. Mol. Biol. 359, 1086-1096.
38. Bosharova, O. V., Makarava, N., Breydo, L., Anderson, M., Salnikov, V. V., and Baskakov, I. V. (2006) Annealing prion amyloid fibrils at high temperature results in extension of a proteinase-K resistant core, J. Biol. Chem. 281, 2371-2379.
39. Foguel, D., and Silva, J. L. (2004) New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies, Biochemistry 43, 11361-11370.
40. Grudzielanek, S., Smirnovas, V., and Winter, R. (2006) Solvation-assisted pressure tuning of insulin fibrillation: From novel aggregation pathways to biotechnological applications, J. Mol. Biol. 356, 497-509.
41. 41.Cordeiro, Y., Kraineva, J., Ravindra, R., Lima, L. M., Gomes, M. P., Foguel, D., Winter, R., and Silva, J. L. (2004) Hydration and packing effects on prion folding and β-sheet conversion. High pressure spectroscopy and pressure perturbation calorimetry studies, J. Biol. Chem. 279, 32354-32359.
42. Lansbury, P. T., and Lashuel, H. A. (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic, Nature 443, 774-779.
43. Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L., and van der Putten, H. (2003) Part II: α-Synuclein and its molecular pathophysiological role in neurodegenerative disease, Neuropharmacology 45, 14-44.
44. Shimoda, K., Sauve, Y., Marini, A., Schwartz, J. P., and Commissiong, J. W. (1992) A high percentage yield of tyrosine hydroxylase-positive cells from rat E14 mesencephalic cell culture, Brain Res. 586, 319-331.
45. Takenouchi, T., Hashimoto, M., Hsu, L. J., Mackowski, B., Rockenstein, E., Mallory, M., and Masliah, E. (2001) Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human α-synuclein, Mol. Cell. Neurosci. 17, 141-150.
46. Lee, H. J., Patel, S., and Lee, S. J. (2005) Intravesicular localization and exocytosis of α-synuclein and its aggregates, J. Neurosci. 25, 6016-6024.
47. Silveira, J. R., Raymond, G. J., Hughson, A. G., Race, R. E., Sim, V. L., Hayes, S. F., and Caughey, B. (2005) The most infectious prion protein particles, Nature 437, 257-261.
48. BI061871+